Since its FDA approval in December 2005, sorafenib (Nexavar®) has been in use for the treatment of metastatic renal cell carcinoma. With this increased use have come reports of adverse effects of sorafenib. To the best of the authors’ knowledge, they are the first to describe an 80-year-old Asian male…
Two cases of hypereosinophilic syndrome that illustrate different variants are reported. Recognition of the specific variant is important because the treatments differ. Patients with hypereosinophilic syndrome should be monitored for evidence of a myeloproliferative process because treatment with tyrosine kinase inhibitors in these patients is effective and may prevent significant…
Membership grants access to journals, courses and a slew of premium benefits.
Please consider supporting us by choosing an option below:
View Membership Options Make A Tax-Deductable Donation
No Thanks, take me to the site and don't show me this again.